Clinical trialPhase 2Terminated
Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions
- Outcome
- Stopped early. Results posted; no analysis attachedSponsor decision; expiration of available study agent due to long recruitment timeline. (Enrollment)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 19 July 2018
- Ended
- 31 July 2021
- Enrollment
- 4 participants
- Sites
- 1
- Primary outcomes
- 1. Visual Assessment of Enhancement; 2. Adverse Events
- Sponsor type
- Industry
- Results posted
- 23 August 2024
- Last update
- 23 August 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 23 August 2024
- Primary outcome
- 1. Visual Assessment of EnhancementNo enhancement: 0.03mL/kg Dose Group: 0 of 4Weak enhancement: 0.03mL/kg Dose Group: 3 of 4Strong enhancement: 0.03mL/kg Dose Group: 1 of 4Values: ParticipantsTime frame: Up to 24 hours post-dose on Day 1No analysis posted for this outcome (outcome 1)
- Primary outcome
- 2. Adverse Events0.03mL/kg Dose Group: 2 of 40.05mL/kg Dose Group: 0 of 00.08mL/kg Dose Group: 0 of 0Values: ParticipantsTime frame: From the time of signing Informed Consent through 24 hours post-dose, up to a maximum of 11 daysNo analysis posted for this outcome (outcome 2)
- Participants
- 0.03mL/kg Dose Group: 4 started, 4 completed0.05mL/kg Dose Group: 0 started, 0 completed0.08mL/kg Dose Group: 0 started, 0 completed
- Serious adverse events
- 0.03mL/kg Dose Group: 0 of 40.05mL/kg Dose Group: 0 of 00.08mL/kg Dose Group: 0 of 0Participants with at least one serious adverse event, of those at risk, as posted
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is an exploratory, single center, open label, parallel-dose, and prospective study of BR55 contrast-enhanced ultrasonography (CEUS) for characterization of solid pancreatic lesions in subjects with suspected pancreatic ductal adenocarcinoma (PDAC) using transabdominal US.
Detailed description public domain (ClinicalTrials.gov)
Approximately twenty-four (24) subjects with suspected PDAC and scheduled to undergo surgical resection within 30 days (but not before 24 hours) after the transabdominal BR55 CEUS examination will be enrolled into 3 dose groups, 0.03, 0.05, and 0.08 mL/kg, with a maximum of 8 patients in each dose group.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
1. Visual Assessment of Enhancement [Up to 24 hours post-dose on Day 1]. Count Of Participants, Participants. No enhancement: 0.03mL/kg Dose Group (n=4): 0. Weak enhancement: 0.03mL/kg Dose Group (n=4): 3. Strong enhancement: 0.03mL/kg Dose Group (n=4): 1.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
2. Adverse Events [From the time of signing Informed Consent through 24 hours post-dose, up to a maximum of 11 days]. Count Of Participants, Participants. 0.03mL/kg Dose Group (n=4): 2; 0.05mL/kg Dose Group (n=0): 0; 0.08mL/kg Dose Group (n=0): 0.